Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011:2011:286875.
doi: 10.1155/2011/286875. Epub 2011 Nov 24.

Rosiglitazone and fenofibrate additive effects on lipids

Ahmad Slim  1 , Laudino Castillo-Rojas, Eddie Hulten, Jennifer N Slim, Dorette Pearce Moore, Todd C Villines
Affiliations

Rosiglitazone and fenofibrate additive effects on lipids

Ahmad Slim et al. Cholesterol. 2011.

Abstract

Background. To evaluate the effect of rosiglitazone, fenofibrate, or their combined use on plasma lipids in normoglycemic healthy adults. Methods and Results. Subjects were randomized in a double-blind fashion to rosiglitazone + placebo, fenofibrate + placebo, rosiglitazone + fenofibrate, or matching double placebo. The between-group difference in the change in fasting TG, high-density lipoprotein cholesterol (HDL-C), LDL-C, and plasma apolipoproteins A-I, A-II, and C-III level were compared after 12 weeks of treatment. A total of 548 subjects were screened and 41 met the inclusion criteria. After 12 weeks of therapy, the median change in the triglyceride levels showed a significant reduction ranging from 47 to 55 mg per deciliter in the fenofibrate only and rosiglitazone/fenofibrate groups compared with placebo (P = 0.0496). However, the rosiglitazone only group did not show significant change in triglyceride level. The change in the Apo AII showed increase in all the treatment groups compared with placebo (P = 0.009). There was also significant change in the Apo CIII that showed reduction of its level in the fenofibrate only and rosiglitazone/fenofibrate groups (P = 0.0003). Conclusion. Rosiglitazone does not appear to modulate hypertriglyceridemia in patients with elevated triglycerides independent of glucose metabolism.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Median change in lipid profile after treatment.
Figure 2
Figure 2
Median change before and after treatment in Apo subparticle, blood sugar, and weight.
See this image and copyright information in PMC

References

    1. O'Rourke CM, Davis JA, Saltiel AR, Cornicelli JA. Metabolic effects of troglitazone in the Goto-Kakizaki rat, a non-obese and normolipidemic rodent model of non-insulin-dependent diabetes mellitus. Metabolism. 1997;46(2):192–198. - PubMed
    1. Lee M-K, Miles PD, Khoursheed M, et al. Metabolic effects of trogiltazone on fructose-induced insulin resistance in the rat. Diabetes. 1995;43:1435–1439. - PubMed
    1. Ciaraldi TP, Gilmore A, Olefsky JM, Goldberg M, Heidenreich KA. In vitro studies on the action of CS-045, a new antidiabetic agent. Metabolism. 1990;39(10):1056–1062. - PubMed
    1. Troglitazone Study Group. The metabolic effects of troglitazone in non-insulin dependent diabetes. Diabetes. 1997;46(supplement 1):p. 149A.
    1. Coresh J, Kwiterovich PO. Small, dense low-density lipoprotein particles and coronary heart disease risk: a clear association with uncertain implications. Journal of the American Medical Association. 1996;276(11):914–915. - PubMed

LinkOut - more resources